DelistedThis company is no longer listed on the London Stock Exchange.
Synairgen plc
Recent RNS announcements
No recent announcements
Annual Reports
7 Jul 2024
Annual Report and Accounts (to 2023-12-31)
6 Jul 2023
Annual Report and Accounts (to 2022-12-31)
30 Jun 2022
Annual Report and Accounts (to 2021-12-31)
Directors (5)
DM
Dr Mark Parry-BillingsExecutive Chairman
1 yrs 10 mos
JT
Joseph Tregonning ColliverChief Executive Officer
2 yrs 9 mos
MM
Martin MurphyNon-Executive Director
–
RM
Richard MarsdenCompany Director and Board member
–
SW
Simon William HoldenSecretary
5 yrs 7 mos
Company details
Synairgen is a company that specializes in respiratory drug research, development, and marketing. Their primary objective is to create and distribute SNG001, an inhaled interferon beta treatment for COVID-19 that directly targets the lungs as an antiviral solution.
Synairgen is a company that specializes in respiratory drug research, development, and marketing. Their primary objective is to create and distribute SNG001, an inhaled interferon beta treatment for COVID-19 that directly targets the lungs as an antiviral solution.
